Targeting the Keap1/Nrf2 Pathway for Treatment of Chronic Neurodegenerative Diseases

Jeffrey A. Johnson 1Jeffrey A. Johnson, University of Wisconsin, USA, will join Redox Medicine 2024 this June to give a presentation on his latest research: "Targeting the Keap1/Nrf2 Pathway for Treatment of Chronic Neurodegenerative Diseases". 

More information about his findings. 

About Jeffrey A. Johnson

Dr. Johnson received a BS in Biology (1984) and MS in Pharmacology (1986) from the University of Minnesota-Duluth, and a PhD in Environmental Toxicology (1992) from the University of Wisconsin. He did postdoctoral training in the Department of Pharmacology at the University of Washington and spent four years as an assistant professor at the University of Kansas Medical Center before joining the University of Wisconsin School of Pharmacy faculty in 1999.

Dr. Johnson is the Director of the Pharmacology and Toxicology BS program. He is also a member of the Waisman Center, Center for Neuroscience, Neuroscience Training Program, Cellular and Molecular Biology Training Program, MD/PhD Training Program, Molecular and Environmental Toxicology Training Program, and Molecular and Cellular Pharmacology Training Program.

His professional interests include transcriptional control of neuroprotective genes and prevention of neurodegeneration in Parkinson's, Alzheimer's, Huntington's and neuromuscular disease. 

More about Dr. Johnson.

Join us at Redox Medicine 2024 this June and learn more about strategies targeting redox pathways in neurodegenerative diseases. 

Redox Medicine Society
Redox Medicine 2024 Conference
June 27-28 - Paris, France
Press Releases | Newsletters Archive | LinkedIn

Scientific News

  • 1
  • 2
Prev Next

read all news